Search Results - M. Sekeres

  • Showing 1 - 2 results of 2
Refine Results
  1. 1

    P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZ... by H. Erba, D. Pollyea, M. Sekeres, G. Garcia-Manero, K. Seiter, I. DeGutis, P. Kiselev, A. McBride, E. Yu, G. Roboz

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIA... by H. Erba, P. Montesinos, R. Vrhovac, E. Patkowska, H.-J. Kim, P. Zak, P.-N. Wang, T. Mitov, J. Hanyok, L. Liu, A. Benzohra, A. Lesegretain, J. Cortes, A. Perl, M. Sekeres, H. Dombret, S. Amadori, J. Wang, M. Levis, R. Schlenk

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: